LENZ Therapeutics, Inc. (NASDAQ:LENZ) Receives $45.60 Average PT from Brokerages

Shares of LENZ Therapeutics, Inc. (NASDAQ:LENZ) have been assigned a consensus recommendation of “Moderate Buy” from the eight ratings firms that are presently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have given a buy rating to the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $45.60.

A number of brokerages have commented on LENZ. HC Wainwright restated a “buy” rating on shares of LENZ Therapeutics in a research note on Monday, December 15th. Citigroup lowered their target price on LENZ Therapeutics from $52.00 to $26.00 and set a “buy” rating for the company in a research note on Thursday. Wall Street Zen downgraded LENZ Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, March 21st. Weiss Ratings reissued a “sell (d-)” rating on shares of LENZ Therapeutics in a research report on Thursday, January 22nd. Finally, William Blair restated an “outperform” rating on shares of LENZ Therapeutics in a report on Tuesday, March 10th.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in LENZ. Quarry LP acquired a new stake in LENZ Therapeutics during the 3rd quarter valued at $27,000. Bfsg LLC acquired a new position in LENZ Therapeutics in the 3rd quarter worth $30,000. Osaic Holdings Inc. boosted its position in LENZ Therapeutics by 2,146.2% in the 2nd quarter. Osaic Holdings Inc. now owns 1,168 shares of the company’s stock valued at $34,000 after buying an additional 1,116 shares during the last quarter. Tower Research Capital LLC TRC boosted its position in LENZ Therapeutics by 51.4% in the 2nd quarter. Tower Research Capital LLC TRC now owns 1,405 shares of the company’s stock valued at $41,000 after buying an additional 477 shares during the last quarter. Finally, SBI Securities Co. Ltd. grew its stake in shares of LENZ Therapeutics by 9,235.3% during the third quarter. SBI Securities Co. Ltd. now owns 1,587 shares of the company’s stock valued at $74,000 after acquiring an additional 1,570 shares in the last quarter. 54.32% of the stock is currently owned by hedge funds and other institutional investors.

LENZ Therapeutics Stock Performance

NASDAQ:LENZ opened at $8.40 on Friday. The firm has a market capitalization of $263.34 million, a price-to-earnings ratio of -2.99 and a beta of 0.52. The firm’s fifty day simple moving average is $13.75 and its 200 day simple moving average is $23.84. LENZ Therapeutics has a twelve month low of $8.40 and a twelve month high of $50.40.

LENZ Therapeutics (NASDAQ:LENZ) last announced its quarterly earnings results on Tuesday, March 24th. The company reported ($1.16) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.91) by ($0.25). The company had revenue of $1.59 million for the quarter, compared to analysts’ expectations of $3.09 million. On average, analysts predict that LENZ Therapeutics will post -2.18 earnings per share for the current year.

Key LENZ Therapeutics News

Here are the key news stories impacting LENZ Therapeutics this week:

• Positive Sentiment: HC Wainwright raised near-term EPS forecasts for Q1 and Q2 2026 and upgraded FY2026/2027 trajectory (estimates moved closer to break-even), signaling improving visibility on operating performance. (Source: HC Wainwright research note)
• Positive Sentiment: HC Wainwright published a long‑term bullish projection (FY2030 EPS of $3.18), reflecting confidence in LENZ’s longer‑term commercialization or pipeline upside. (Source: HC Wainwright research note)
• Positive Sentiment: Bank of America set a new $29 price target for LENZ, which implies meaningful upside from current levels and may support buy-side interest. LENZ Therapeutics (NASDAQ:LENZ) Given New $29.00 Price Target at Bank of America
• Neutral Sentiment: Recent earnings call materials and coverage are available for review — useful for investors digging into guidance, R&D progress and management comments. Q4 2025 Earnings Call Summary Q4 2025 Earnings Call Transcript Analysts Offer Insights on Healthcare Companies
• Negative Sentiment: HC Wainwright trimmed its Q4 2026 EPS estimate (from -$0.41 to -$0.48) and reduced several multi‑year forecasts (FY2028 and FY2029 down), which increases near‑term earnings uncertainty. (Source: HC Wainwright research notes)
• Negative Sentiment: LENZ reported a Q4 2025 earnings miss (EPS and revenue below consensus), a direct catalyst that likely pressured the stock and prompted analyst revisions. Q4 2025 Earnings Call Summary
• Negative Sentiment: Citigroup cut its price target sharply (from $52 to $26) despite keeping a buy rating — the lower PT reduces near‑term upside expectations from some institutional investors. Citigroup Lowers LENZ Price Target

LENZ Therapeutics Company Profile

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.